Vydura Evrópusambandið - íslenska - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - mígreni kvilla - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Darunavir Medical Valley Filmuhúðuð tafla 600 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

darunavir medical valley filmuhúðuð tafla 600 mg

medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 600 mg

Desirett (Desogestrel) Filmuhúðuð tafla 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

desirett (desogestrel) filmuhúðuð tafla 75 míkróg

exeltis healthcare s.l. - desogestrelum inn - filmuhúðuð tafla - 75 míkróg

Gestrina Filmuhúðuð tafla 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

gestrina filmuhúðuð tafla 75 míkróg

teva b.v.* - desogestrelum inn - filmuhúðuð tafla - 75 míkróg

Cerazette Filmuhúðuð tafla 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cerazette filmuhúðuð tafla 75 míkróg

n.v. organon* - desogestrelum inn - filmuhúðuð tafla - 75 míkróg

Melleva Filmuhúðuð tafla 0,15 mg/0,03 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

melleva filmuhúðuð tafla 0,15 mg/0,03 mg

exeltis healthcare s.l. - levonorgestrelum inn; ethinylestradiolum inn - filmuhúðuð tafla - 0,15 mg/0,03 mg

Mercilon Tafla 150 míkróg/20 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mercilon tafla 150 míkróg/20 míkróg

n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg

Primolut N Tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

primolut n tafla 5 mg

bayer ab* - norethisteronum inn - tafla - 5 mg

Orserdu Evrópusambandið - íslenska - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Vanflyta Evrópusambandið - íslenska - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.